Abstract
In this perspective, we present our assessment of all of the known accumulated evidence on the role of neoadjuvant therapy in the management of borderline resectable pancreatic cancer highlighting the gaps in the data, the current regimens used and providing a brief insight into the way forward.
| Original language | English |
|---|---|
| Pages (from-to) | 249-254 |
| Number of pages | 6 |
| Journal | Indian Journal of Surgical Oncology |
| Volume | 15 |
| Issue number | Suppl 2 |
| Early online date | 1 Jul 2021 |
| DOIs | |
| Publication status | Published - May 2024 |
Keywords
- Neoadjuvant therapy
- Pancreatic cancer
- Surgical resection
